Retatrutide: The Triple Agonist That Could Change Everything
Retatrutide targets three hormone receptors simultaneously, producing the most dramatic weight loss results of any medication tested to date. Here is everything you need to know about this next-generation treatment.
Medical Disclaimer: Retatrutide is an investigational medication with ongoing clinical trials. Information here is based on published clinical trial data and may change as more research becomes available. Consult your healthcare provider about current availability and eligibility.
If semaglutide was the first generation and tirzepatide was the second, retatrutide represents the third wave of GLP-1-based obesity medications. By adding glucagon receptor activation to the established GLP-1 and GIP mechanisms, retatrutide achieves weight loss results that were previously thought impossible with medication alone.
How Retatrutide Works: The Triple Mechanism
| Receptor | Effect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|---|
| GLP-1 | Appetite suppression, slowed gastric emptying, insulin secretion | Yes | Yes | Yes |
| GIP | Enhanced insulin response, fat metabolism, possible nausea buffering | No | Yes | Yes |
| Glucagon | Increased energy expenditure, liver fat reduction, thermogenesis | No | No | Yes |
The glucagon component is what makes retatrutide unique. While GLP-1 and GIP primarily work by reducing caloric intake (eating less), glucagon increases energy expenditure (burning more). This dual approach — eating less AND burning more — is why retatrutide produces such dramatic results.
Phase 2 Clinical Trial Results
The Phase 2 trial (published in the New England Journal of Medicine, 2023) enrolled 338 adults with obesity. Results at 48 weeks by dose:
| Dose | Average Weight Loss | Patients Losing 15%+ |
|---|---|---|
| 1mg | 8.7% | 27% |
| 4mg | 17.1% | 75% |
| 8mg | 22.8% | 91% |
| 12mg | 24.2% | 93% |
| Placebo | 2.1% | 2% |
Key finding: At the 12mg dose, 93% of patients lost at least 15% of their body weight, and the average loss was 24.2% — approximately 58 pounds for a 240-pound starting weight. The weight loss curve was still trending downward at 48 weeks, suggesting even greater potential with longer treatment.
Benefits Beyond Weight Loss
Liver Fat Reduction
The glucagon receptor is highly expressed in the liver, and retatrutide showed remarkable liver fat reduction in clinical trials. This makes it potentially the most effective medication for non-alcoholic fatty liver disease (NAFLD/MASH). Some patients showed near-complete resolution of liver fat.
Metabolic Improvements
- HbA1c reduction comparable to or exceeding tirzepatide
- Significant improvements in triglycerides and cholesterol
- Blood pressure reduction
- Improved insulin sensitivity
Side Effect Profile
Phase 2 data showed a GI side effect profile similar to other GLP-1 medications, though with some differences:
- Nausea: 16-43% depending on dose (comparable to tirzepatide)
- Diarrhea: 16-26%
- Vomiting: 6-16%
- Constipation: 6-14%
- Heart rate increase: Small increases observed, likely from glucagon component
- Discontinuation rate: 6% at 12mg dose
The glucagon component raises theoretical concerns about blood sugar elevation in diabetic patients (glucagon raises blood sugar), but the GLP-1 and GIP components appear to counterbalance this effect.
How It Compares
Head-to-Head Comparison
- vs. Semaglutide: Retatrutide produces approximately 60% more weight loss. Better liver fat reduction. More complex mechanism. Less long-term safety data.
- vs. Tirzepatide: Slightly more weight loss (24% vs 22%). Additional glucagon mechanism may offer metabolic advantages. Similar GI side effect rates. No head-to-head trials yet.
- Unique advantage: The energy expenditure component means retatrutide works even when patients are eating "normally" — it burns more calories, not just reduces intake.
Current Availability and Timeline
- Phase 3 trials: Currently enrolling and underway for obesity and type 2 diabetes
- Expected FDA approval: Late 2026-2027 (estimated, subject to trial results and FDA review timeline)
- Brand name: Not yet announced
- Compounded availability: May be available through compounding pharmacies. Contact Trimi for current status
Who Should Consider Retatrutide?
- Patients who have not achieved adequate results with semaglutide or tirzepatide
- Patients with significant fatty liver disease
- Those seeking the maximum possible weight loss
- Patients who want the "burn more" mechanism in addition to "eat less"
- Those comfortable with a newer medication that has less long-term data
Frequently Asked Questions
What is retatrutide?
Retatrutide (LY3437943) is a triple hormone receptor agonist developed by Eli Lilly. It activates GLP-1, GIP, and glucagon receptors simultaneously. This triple mechanism produced the highest weight loss results seen in any obesity medication trial to date — up to 24.2% body weight loss in Phase 2.
When will retatrutide be FDA-approved?
Retatrutide is currently in Phase 3 clinical trials. Based on typical timelines, FDA approval could come in late 2026 or 2027 if trials are successful. Compounded retatrutide may be available through providers like Trimi before formal brand-name approval.
How does retatrutide compare to tirzepatide?
Tirzepatide is a dual agonist (GLP-1/GIP) while retatrutide adds a third target (glucagon). The glucagon component may increase energy expenditure (calorie burning) in addition to reducing appetite, which could explain the greater weight loss. However, head-to-head trials have not been completed.
What are the side effects of retatrutide?
Phase 2 data showed similar GI side effects to other GLP-1 medications: nausea (varying by dose), diarrhea, vomiting, and constipation. The glucagon component may increase heart rate slightly. Long-term safety data is still being collected through Phase 3 trials.
Explore Your Options with Trimi
Whether you are interested in semaglutide ($99/mo), tirzepatide ($125/mo), or retatrutide, our clinicians help you find the right fit.
Get Started TodaySources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).